W. Wuyts (Leuven, Belgium), N. Chaudhuri (Limavady, United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
This session includes the Best Abstract for Assembly 12 - Interstitial Lung Diseases, entitled "Results of a phase 2 study of GLPG1205 for idiopathic pulmonary fibrosis (PINTA)”
Prognostic significance of dose reduction of antifibrotics in patients with IPF
S. Porse (Hellerup, Denmark), N. Hoyer (Hellerup, Denmark), T. Skovhus Prior (Aarhus, Denmark), E. Bendstrup (Aarhus, Denmark), S. B. Shaker (Hellerup, Denmark)
|    |
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe.
T. Karampitsakos (Patras, Greece), N. Mogulkoc (Izmir, Turkey), M. Kreuter (Heidelberg, Germany), W. Wuyts (Leuven, Belgium), S. Tomassetti (Florence, Italy), E. Bendstrup (Aarhus, Denmark), M. Molina-Molina (Barcelona, Spain), P. Spagnolo (Padova, Italy), E. Manali (Athens, Greece), Ö. Unat (Izmir, Turkey), N. Kahn (Heidelberg, Germany), L. Kolilekas (Athens, Greece), E. Rosi (Florence, Italy), L. Gori (Florence, Italy), C. Ravaglia (Forlì, Italy), Z. Daniil (Larissa, Greece), T. Prior (Aarhus, Denmark), I. Papanikolaou (Corfu, Greece), S. Aso (Barcelona, Spain), S. Tryfon (Thessaloniki, Greece), D. Papakosta (Thessaloniki, Greece), E. Balestro (Padova, Italy), S. Papiris (Athens, Greece), K. Antoniou (Heraklion, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Patras, Greece)
| |
Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry
M. Kreuter (Heidelberg, Germany), H. Kabitz (Konstanz, Germany), L. Hagmeyer (Solingen , Germany), P. Hammerl ( Immenhausen, Germany), A. Esselmann (Warendorf, Germany), C. Wiederhold (Fulda, Germany), D. Skowasch (Bonn, Germany), C. Stolpe (Ibbenbüren, Germany), M. Joest (Bonn, Germany), S. Veitshans (Böblingen, Germany), M. Höffgen (Rheine, Germany), P. Maqhuzu (Neuherberg, Germany), L. Schwarzkopf (Munich , Germany), A. Hellmann (Rheine , Germany), M. Pfeifer (Donaustauf, Germany), J. Behr (Munich , Germany), R. Karpavicius (Essen , Germany), A. Günther (Gießen , Germany), F. Herth (Heidelberg , Germany), P. Markart (Fulda, Germany)
| |
STARLINER study, disease behaviour assessed by a wide range of parameters including patient-reported outcomes (PRO) results
E. Bendstrup (Aarhus, Denmark), M. Wijsenbeek (Rotterdam, Netherlands), C. Valenzuela (Madrid, Spain), M. Henry (Cork, Ireland), M. Bengus (Basel, Switzerland), F. Gilberg (Basel, Switzerland), K. Kirchgaessler (Basel, Switzerland), C. Vancheri (Catania, Italy)
| |
Profile of antimicrobial peptides in the bronchoalveolar lavage of patients with interstitial lung diseases
R. Osuna Gómez (Barcelona, Spain), S. Orozco Echevarria (Barcelona, Spain), P. Millán Billi (Barcelona, Spain), S. Vidal Alcorisa (Barcelona, Spain), D. Castillo Villegas (Barcelona, Spain)
| |
LSC - 2021 - The effect of long-term personal air pollution exposure on the inflammatory mediators in Idiopathic Pulmonary Fibrosis
T. Ioannis, K. Dimakopoulou (kdimakop@med.uoa.gr / Department of Hygiene, E. and Medical Statistics, M. School, N. and Kapodistrian University of Athens,Athens), E. Manali (fmanali@otenet.gr / 2nd Pulmonary Medicine Department, M. School, N. and Kapodistrian University of Athens, “. University Hospital,Haidari), A. Karakatsani (akarakats@med.uoa.gr / 2nd Pulmonary Medicine Department, M. School, N. and Kapodistrian University of Athens, “. University Hospital,“This research is co-financed by Greece and the European Union (European Social Fund-ESF) through the Operational Programme “Human Resources Development, E. and Lifelong Learning 2014-2020 in the context of the project “The effects of air pollution exposure on patients with idiopathic pulmonary fibrosis” (MIS 5048157).”)
| |
Validation of the artificial intelligence software to detect chronic fibrosing interstitial lung diseases in chest X-ray
H. Nishikiori (Sapporo, Japan), K. Hirota (Sapporo, Japan), T. Suzuki (Tokyo, Japan), Y. Takagi (Tokyo, Japan), S. Honda (Tokyo, Japan), K. Ikeda (Sapporo, Japan), Y. Mori (Sapporo, Japan), Y. Asai (Sapporo, Japan), N. Yama (Sapporo, Japan), H. Ohnishi (Sapporo, Japan), M. Hatakenaka (Sapporo, Japan), H. Chiba (Sapporo, Japan)
| |